Investment Rating - The industry investment rating is "Positive" and maintained [11] Core Insights - As of Q2 2025, the A-share environmental sector's heavy positions accounted for 0.24%, reflecting a slight increase of 0.01 percentage points from the previous quarter. The overall market is currently in a low allocation state, with a standard allocation ratio of 1.06% [6][18] - The top ten heavy positions in public funds totaled approximately 7.64 billion yuan, representing 0.25% of all disclosed fund stock holdings. The leading companies in terms of heavy positions include Hanlan Environment (1.21 billion yuan), Weiming Environmental (1.19 billion yuan), and Longjing Environmental (610 million yuan) [2][29] Summary by Sections Fund Holdings - The heavy position ratio for the A-share environmental sector was 0.24% at the end of Q2 2025, with a slight increase of 0.01 percentage points. A total of 320 fund products held heavy positions in environmental companies, accounting for 4.15% of all disclosed fund products [6][18] - The top heavy positions by market value were Hanlan Environment (1.21 billion yuan), Weiming Environmental (1.19 billion yuan), Longjing Environmental (610 million yuan), Huicheng Environmental (540 million yuan), and Juguang Technology (530 million yuan) [29][34] Market Trends - The environmental sector is experiencing a valuation recovery driven by multiple factors, including market preference for solid waste incineration stocks, which are expected to benefit from public utility market reforms and carbon market expansion [8][36] - The report highlights a positive outlook for the second half of 2025, particularly for solid waste incineration and water assets, with recommended stocks including Hanlan Environment, Weiming Environmental, and others [36][37] Company Performance - The number of funds holding significant positions in companies like Hanlan Environment (56 funds), Guangda Environment (21 funds), and others indicates a growing market interest [7][23] - Notable changes in heavy stock market value ratios include significant increases for Shanghai Xiba (up 4.63 percentage points) and Huicheng Environmental (up 1.39 percentage points) [34][36] Investment Strategy - The report suggests a focus on companies transitioning towards ToB (business-to-business) models, which is expected to enhance cash flow and support valuation recovery. Key companies to watch include Hanlan Environment, Guangda Environment, and others [36][39] - The environmental sector is seen as having a solid growth trajectory, with specific attention to waste incineration, water services, and testing services as areas of potential investment [39][40]

Investment Rating - The report maintains a "Buy" rating for the company [13] Core Views - The report discusses the potential for valuation recovery and strong performance support for the company, suggesting that concerns over overseas trade policies and profit capabilities will diminish by 2025H2-2026, leading to a restoration of reasonable valuation levels [4][10][24] Summary by Sections Historical Performance and Valuation Decline - The company has shown strong performance over the past 2-3 years, consistently exceeding expectations, yet its valuation has been under pressure due to concerns about declining profitability and increasing trade barriers in the U.S. [9][23] Valuation Outlook - The report anticipates a gradual resolution of concerns regarding profitability and trade barriers, with the company entering a valuation recovery phase by 2025H2-2026. The expected PE ratio could recover to a range of 15-20 times [10][53] Profit Outlook - Even under pessimistic scenarios, the company is projected to achieve a profit of around 11 billion, with potential contributions from the U.S. market and domestic large storage demand supporting overall performance [11][54]

公司发布股东大冢出售股权公告 核心观点 公司股东结构变更有利于公司治理改善、国资赋能、不良资产处置、并购整合，加快成为全球医疗器械 龙头之一的步伐。近期医疗器械关注度提升，产品创新有望产生持续催化、国际化和并购打开长期空 间。医保局领导表示集采不再唯低价论，建议关注医疗器械板块反内卷、估值修复和拐点机会。微创医 疗作为国内创新医疗器械龙头，处于估值低位，我们看好公司投资价值。 事件 机构：中信建投证券 研究员：贺菊颖/王在存/郑涛 风险提示 2025 年7 月25 日，公司股东大冢订立协议，有条件同意向若干买方出售290,670,408 股公司股份。买方 包括上海上实资本管理有限公司旗下基金、We'Tron Capital Limited 及公司管理层的投资平台。 简评 根据公司公告，股东大冢将出售290,670,408 股股权（ 占总股本的15.71%），待交易结束之后，大冢持 股从20.7%下降至4. 99 %，上实资本管理有限公司旗下基金持股7.31%；We'Tron CapitalLimited 持股比 例由18.67%提升至25.98%。 1）集中带量采购降价幅度超预期：未来不排除公司现有商业化产品 ...

Core Viewpoint - The report highlights the stable profitability and attractive dividend yield of Industrial and Commercial Bank of China (ICBC), positioning it as a favorable investment opportunity in the Hong Kong banking sector [1][5]. Group 1: Profitability and Dividend Yield - ICBC has maintained a compound annual growth rate (CAGR) of 3.2% in net profit attributable to shareholders from 2019 to 2024, supported by stable asset quality and improving credit costs, sustaining a return on equity (ROE) around 11.5% [1]. - The projected dividend yield for ICBC in 2025 is approximately 5.6%, the highest among major Hong Kong banks, which is expected to attract long-term capital inflows [1]. - Despite a challenging operating environment, ICBC's revenue and profit performance in Q1 2025 may be temporarily below expectations, but a return to positive growth for the full year is likely [1]. Group 2: Credit Growth and Structure - From 2019 to 2024, ICBC's credit growth has a CAGR of about 11.1%, aligning with the average of the four major banks [2]. - The corporate lending segment has contributed 65% of the credit increment, with government-related infrastructure loans accounting for 43.4% of total loan growth [2]. - Since 2022, ICBC has increased lending to emerging sectors such as manufacturing and green industries, optimizing its credit structure [2]. Group 3: Interest Margin and Cost of Funds - ICBC's net interest margin in Q1 2025 was 1.33%, slightly below the average of the four major banks [3]. - The bank's deposit cost for 2024 is estimated at 1.72%, which is better than the average of its peers, but it has faced faster declines in loan pricing [3]. - The central bank's focus on financial stability is expected to support a stabilization of ICBC's interest margin in the future [3]. Group 4: Asset Quality - ICBC's non-performing loan (NPL) ratio decreased to 1.33% in Q1 2025, reflecting a cumulative decline of 25 basis points since 2020 [4]. - The bank's provision coverage ratio remains high at 215.7%, indicating strong asset quality management [4]. - While corporate loan quality is improving, retail loan risks have started to emerge, with the retail NPL ratio increasing to 1.34% in 2024 [4]. Group 5: Investment Recommendation - The banking sector is increasingly characterized by a "dumbbell" structure, with state-owned banks like ICBC positioned as stabilizing forces [5]. - The forecasted growth rates for net profit attributable to shareholders from 2025 to 2027 are 0.9%, 3.1%, and 4.3%, respectively [5]. - Given ICBC's stable ROE and attractive dividend yield, a target price-to-book (PB) ratio of 0.64x for 2025 is suggested, indicating a potential upside of 25% [5].

Investment Rating - The industry investment rating is "Positive" and maintained [8] Core Viewpoints - Since 2024, some waste incineration and water service companies have announced reductions in loan interest rates and financial expenses, which are expected to contribute positively to their performance in a low-interest environment [2][16] - The report emphasizes the importance of focusing on companies with stable performance, increased dividends, valuation recovery, and declining borrowing costs in the waste incineration and water service sectors [6][40] Summary by Sections Debt Situation - Waste incineration and water service projects typically have a high debt financing ratio, often around 70%. These projects require significant upfront investment over 1-2 years, followed by a 20-30 year period to recover costs through operational income [4][17] - As of the end of 2024, the outstanding debt for major companies in the sector includes: - China Everbright International: 91.7 billion HKD - Conch Venture: 28.2 billion HKD - Hanlan Environment: 16.3 billion CNY - Beijing Enterprises Water Group: 75.5 billion CNY - Yuehai Investment: 23.9 billion HKD - Xingrong Environment: 14.8 billion CNY [4][17] Trends in Debt Ratios - The debt ratio for waste incineration companies has shown a declining trend over the past two years, while the increase in water service companies' debt ratios has slowed down [5][21] Impact of Borrowing Costs - Since 2018, interest rates have been on a downward trend, and as new project loan rates decrease, some companies are replacing high-interest loans. This could lead to further reductions in borrowing costs, positively impacting the performance of waste incineration and water service companies [6][31] - The report recommends focusing on companies in the waste incineration and water service sectors that exhibit stable performance and declining borrowing costs, highlighting companies such as Hanlan Environment, Xingrong Environment, China Everbright International, and others [6][40] Performance Sensitivity to Borrowing Costs - If the average borrowing cost decreases by 10, 30, or 50 basis points in 2025, the estimated profit elasticity for leading companies such as Beijing Enterprises Water Group, China Everbright International, and Green Power will be 3.62%, 10.86%, and 18.10% respectively [38] - If the average borrowing cost reaches 2.50% in 2025, the profit elasticity for top companies will be significantly higher, with estimates of 28.28% for Yuehai Investment and 20.57% for Beijing Enterprises Water Group [38] Industry Growth and Transformation - The waste incineration and water service sectors are experiencing steady growth, improved cash flow, and increased dividends. Recent market reforms are pushing the industry towards a transformation from government-oriented (To G) to business and consumer-oriented (To B, To C) models, which is expected to accelerate valuation recovery [6][40]

Core Viewpoint - The recent optimization of drug procurement rules in China aims to prevent excessive competition and ensure reasonable price reductions in the pharmaceutical industry, reflecting a shift towards a more sustainable market environment [1][2][3]. Group 1: Policy Changes - The new drug procurement rules will no longer solely rely on the lowest bid as the benchmark, requiring companies to justify their pricing and ensure it does not fall below cost [1]. - The optimization of procurement rules is seen as a necessary response to the negative impacts of excessive competition, particularly in high-value medical consumables [2][3]. - The shift in policy is part of a broader strategy to enhance procurement evaluation and promote standardized practices, indicating a consensus at the national level [3]. Group 2: Market Impact - Following the announcement, companies like Nanwei Medical and Anjisi, which were significantly affected by low-price competition, experienced positive stock performance [2]. - The changes in procurement policy are expected to create a more favorable competitive environment for companies, moving towards a "post-price reduction era" where quality development is emphasized [3]. Group 3: Company Performance - BluFan Medical, a key player in the cardiovascular high-value consumables sector, is anticipated to achieve better performance due to the "anti-involution" policy shift, with projected sales exceeding 690 million yuan in the first half of 2025, representing over 20% growth year-on-year [4]. - The company has built a comprehensive product matrix in the cardiovascular medical device field, which has allowed it to significantly increase its market share despite previous price pressures from procurement policies [4][6]. - With a cumulative R&D investment of 2 billion yuan from 2018 to 2024, BluFan Medical is positioned to benefit from recent innovations and policy support for high-quality drug and device development [5][6]. Group 4: Industry Outlook - The ongoing reforms in the medical industry are expected to accelerate recovery in the high-value consumables market, with BluFan Medical leading the narrative of valuation recovery and business growth [7]. - Other companies in the sector, such as Sanyou Medical and Nanwei Medical, are also experiencing improved market conditions due to the easing of procurement pressures and the introduction of new products [6][7].

上 市 公 司 公 司 研 究 / 公 司 报 告 报告原因：首次覆盖 买入（首次评级） | 市场数据： | 2025 年 07 月 25 日 | | --- | --- | | 收盘价（港币） | 6.09 | | 恒生中国企业指数 | 9150.49 | | 52 周最高/最低（港币） | 6.48/4.06 | | H 股市值（亿港币） | 21,705.14 | | 流通 H 股（百万股） | 86,794.04 | | 汇率（人民币/港币） | 1.0991 | 一年内股价与基准指数对比走势： -5% 45% 95% HSCEI 工商银行 资料来源：Bloomberg 证券分析师 郑庆明 A0230519090001 zhengqm@swsresearch.com 林颖颖 A0230522070004 linyy@swsresearch.com 冯思远 A0230522090005 fengsy@swsresearch.com 李禹昊 A0230525070004 liyh2@swsresearch.com 联系人 李禹昊 (8621)23297818× liyh2@swsresearch.com ...

Market Overview - The three major indices in A-shares collectively rose, with the Shanghai Composite Index up by 0.12% closing at 3,597.94 points, the Shenzhen Component Index up by 0.44% at 11,217.58 points, and the ChiNext Index up by 0.96% at 2,362.60 points [2][6] - The total trading volume in the Shanghai and Shenzhen markets reached 174.23 billion, a decrease of 45 billion compared to last Friday [2] Index Performance - The indices experienced a brief drop before rebounding in the afternoon session, ultimately closing in positive territory [5][6] - The performance of individual stocks showed a mixed trend, with half of the stocks rising and half falling [7] Sector Analysis - The financial sector, particularly insurance, showed strong performance, with the insurance sector reaching a peak increase of 2.48% [8] - New China Life Insurance reached a historical high, supported by growth in premiums and revenues, alongside a mandatory 30% investment in equity markets [9] - Conversely, the commodities sector faced significant declines, with the coal industry dropping by 2.89%, steel by 2.01%, and energy metals by 1.8% [9] Economic Outlook - There is uncertainty regarding whether A-shares have entered a new economic upcycle, with management expressing a stable outlook and emphasizing three certainties: high-quality economic development, macro policy expectations, and asset valuation recovery [10] - The average P/E ratio for the Shanghai Composite Index is currently at 15.56, compared to historical highs of 18.40 [12] Key Contributors - The significant rise in the Shenzhen Component and ChiNext indices was largely attributed to the performance of Ningde Times, which saw its H-shares increase by 6.65% [13][15] - The integrated circuit and printing sectors also contributed significantly to the performance of these indices, with Deep Rainbow Technology rising over 17% [15]

Group 1 - The banking sector's short-term adjustments do not alter the long-term positive outlook, with incremental capital inflows driving valuation recovery [1] - The banking sector's price-to-book (PB) ratio has increased from 0.66 to 0.73 since the beginning of the year, indicating further recovery potential towards a PB of 1 [1] - The high dividend yield of 4.47% as of July 18 ranks second among 35 Wind secondary industries, while the PB ratio remains at 0.73 [1] Group 2 - There is a clear expectation of marginal improvement in fundamentals, with net interest margins stabilizing due to easing credit supply-demand conflicts and a gradual decline in loan rates [1] - Non-interest income is continuously improving, driven by a recovery in wealth management and a narrowing decline in middle-income, benefiting from the recovery in the bond market [1] - Asset quality pressure is alleviating, contributing to the overall positive outlook for the banking sector [1] Group 3 - In a low-interest-rate environment, the high dividend and quasi-fixed income attributes of banks are particularly attractive, suggesting that the valuation recovery driven by capital flows is likely to continue [2] - The 180 Financial Index, which tracks representative securities in the financial sector, reflects the overall performance of listed companies in banking, insurance, and securities [2] - Investors without stock accounts can consider the Guotai CSI 180 Financial ETF Connect C and A for exposure to the financial sector [2]

Group 1 - The recent policy shift in the medical device industry breaks the "low-price only" rule in centralized procurement, allowing for a more balanced evaluation of bids, which is expected to lead to a significant rebound in the sector [2] - The medical device index's rolling P/E ratio is currently at 37.30, with a premium of 176.16% over the CSI 300 index, indicating that the sector is at an absolute low compared to the market over the past decade [4] - The medical device sector is experiencing a strong internal recovery force as the restrictive "low-price only" procurement policy has loosened, suggesting that valuation recovery is imminent [4][7] Group 2 - The medical device ETF (159898) has seen a year-to-date increase of approximately 10% and has experienced significant net inflows, indicating strong investor interest and a potential "buying signal" [5][7] - Leading companies in the medical device sector, such as Mindray Medical and United Imaging, are expected to face reduced pricing pressure, supported by policies encouraging equipment upgrades in the second half of the year [8] - The current low valuations in the medical device sector provide a safety margin and substantial upside potential, making it an attractive opportunity for investors [7]